Based on far better efficacy and safety than other previous treatments, the FDA approved selpercatinib and pralsetinib for adult patients with metastatic RET fusion-positive NSCLC in 2020, while the National Medical Products Administration of China granted accelerated approval for pralsetinib in 2021. The gene discussed is RET; the disease is non-small cell lung carcinoma.